Hence, treatment with a GH-releasing hormone agonist increases IGF-1 levels, thereby decreasing NASH activity score and hepatocyte ballooning without altering steatosis.63 On the other hand, IGF binding protein-7 was shown to be directly correlated with the degree of steatosis and fibrosis in NASH.63 A study in a GH-deficient and hepatic IGF-1-deficient mouse model showed increased hepatic triglycerides after GH treatment.62 These findings suggest that IGF-1 plays a role in liver adiposity along with GH itself. Here, IGFBP7 is linked to metabolic dysfunction-associated steatohepatitis.